{"id":17861,"date":"2026-05-15T14:21:42","date_gmt":"2026-05-15T06:21:42","guid":{"rendered":"https:\/\/y2nbc5qg9c-staging.wpdns.site\/yonglirongs-new-amniotic-fluid-stem-cell-drug-received-dual-fast-track-certification-for-regenerative-medicine\/"},"modified":"2026-10-22T15:28:19","modified_gmt":"2026-10-22T07:28:19","slug":"yonglirongs-new-amniotic-fluid-stem-cell-drug-received-dual-fast-track-certification-for-regenerative-medicine","status":"publish","type":"post","link":"https:\/\/u-neuron.com\/en\/yonglirongs-new-amniotic-fluid-stem-cell-drug-received-dual-fast-track-certification-for-regenerative-medicine\/","title":{"rendered":"U-NEURON&#8217;s Amniotic Fluid Stem Cell New Drug Secures Dual ExpeditedRegulatory Guidance for Regenerative Medicine"},"content":{"rendered":"&#13;\n<p class=\"wp-block-paragraph\">Yongliron (<a href=\"https:\/\/www.cnyes.com\/twstock\/6973\" rel=\"nofollow noopener\" target=\"_blank\">U-NEURON (6973-TW) announced today (22nd) that its proprietary new drug candidate UA002, designed for the treatment of erectile dysfunction, has been approved by Taiwan TFDA under the &#8220;Project-Based Advisory and Guidance Cases&#8221; scheme. Concurrently, UA002 secured the &#8220;Flagship Project&#8221; (Index Case) qualification from the Center for Drug Evaluation (CDE). Under this dedicated advisory framework, the company expects to accelerate development and regulatory review while mitigating R&amp;D risks, marking dual expeditedregulatory support in the regenerative medicine arena.<\/a>) announced today (22nd) that its new drug for the treatment of erectile dysfunction, UA002, has been approved by the TFDA of the Ministry of Health and Welfare to be included in the &#8220;Drug Project Consultation and Guidance Case&#8221;, and has also been approved by the Drug Inspection Center. CDE&#8217;s &#8220;index case&#8221; qualification is expected to accelerate the development and review process and reduce the development process under the project guidance mechanism in the future, just like obtaining double fast-track certification in the regenerative medical market.\u00a0<\/p>&#13;\n&#13;\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"640\" height=\"360\" class=\"wp-image-17353\" src=\"https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/05\/6118ab83595bb68dff1e860b050b17de.jpg\" alt=\"cover image of news article\" title=\"\" srcset=\"https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/05\/6118ab83595bb68dff1e860b050b17de.jpg 640w, https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/05\/6118ab83595bb68dff1e860b050b17de-400x225.jpg 400w, https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/05\/6118ab83595bb68dff1e860b050b17de-430x242.jpg 430w, https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/05\/6118ab83595bb68dff1e860b050b17de-150x84.jpg 150w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/>&#13;\n<figcaption class=\"wp-element-caption\">(Photo: Shutterstock)\nU-NEURON noted that UA002 is an in-house developed amniotic fluid stem cell candidate. Having completed Phase 1 patient enrollment with validated safety and preliminary efficacy profiles, UA002 is currently undergoing Phase 2a clinical trials.<\/figcaption>&#13;\n<\/figure>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">\u00a0<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">U-NEURON explained that under the TFDA &#8220;Project-Based Advisory and Guidance Cases&#8221; and CDE &#8220;Flagship Project&#8221; mechanisms, regulatory authorities will assign dedicated project officers to provide end-to-end guidance spanning regulatory strategy, clinical trial design, manufacturing and quality controls (CMC), through to market approval submission. This integrated support is anticipated to substantially shorten drug development and review timelines while reducing overall R&amp;D costs.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">\u00a0<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">U-NEURON further highlighted that the TFDA updated its advisory guidelines this year to formally include regenerative medicinal products within its scope, establishing clear regulatory pathways and review frameworks.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Chief Operating Officer Shin-Yi Chuang stated that following the enactment of the two regenerative medicine laws (the Regenerative Medicine Actand the Regenerative Medicinal Products Act), the company will collaborate closely with regulatory agencies to advance UA002 along an optimized development route.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">U-NEURON Chairman Dr. Frank Chien added that the implementation of the tworegenerativemedicinelaws serves as a major catalyst for the industry. However, as clear guidance is crucial during early regulatory rollout, securing TFDA and CDE project guidance enables UA002 to leverage agency support, concentrating resources to expedite R&amp;D and commercialization.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Addressing market prospects, data from market research firm Global Market Insights indicates that the global erectile dysfunction therapeutics market is projected to expand at a compound annual growth rate (CAGR) of 9.2% from 2025, reaching a market value of approximately US$7 billion by 2034.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Addressing market prospects, data from market research firm Global Market Insights indicates that the global erectile dysfunction therapeutics market is projected to expand at a compound annual growth rate (CAGR) of 9.2% from 2025, reaching a market value of approximately US$7 billion by 2034.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/news.cnyes.com\/news\/id\/6284522?utm_source=chatgpt.com\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/news.cnyes.com\/news\/id\/6284522?utm_source=chatgpt.com<\/a><\/p>&#13;\n","protected":false},"excerpt":{"rendered":"<p>U-NEURON (6973-TW) announced today (22nd) that its proprietary new drug candidate UA002, designed for the treatment of erectile dysfunction, has been approved by Taiwan TFDA under the &#8220;Project-Based Advisory and Guidance Cases&#8221; scheme. Concurrently, UA002 secured the &#8220;Flagship Project&#8221; (Index Case) qualification from the Center for Drug Evaluation (CDE). Under this dedicated advisory framework, the company expects to accelerate development and regulatory review while mitigating R&#038;D risks, marking dual expeditedregulatory support in the regenerative medicine arena.<\/p>\n","protected":false},"author":15,"featured_media":17862,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[235,236,237],"tags":[],"class_list":["post-17861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investor-zone","category-media-reports","category-new-drug-development-and-regulation"],"acf":[],"_links":{"self":[{"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/posts\/17861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/comments?post=17861"}],"version-history":[{"count":11,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/posts\/17861\/revisions"}],"predecessor-version":[{"id":18376,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/posts\/17861\/revisions\/18376"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/media\/17862"}],"wp:attachment":[{"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/media?parent=17861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/categories?post=17861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/tags?post=17861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}